News | September 28, 2012

Accumetrics Aligned with Medicare’s Hospital Readmissions Reduction Program

September 28, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced the launch of its Quality Improvement and Value Assessment Program. The program is designed to help hospitals measure the potential reduction in 30-day hospital readmissions and length of stay as a result of integrating platelet reactivity testing into cardiovascular patient care. As a key quality metric, 30-day readmissions were recently highlighted by Medicare, which next month will begin penalizing hospitals for excess 30-day readmission rates.

“With the advent of Medicare’s Hospital Readmissions Reduction Program, healthcare providers face increasing pressure to improve patient care while reducing overall cost. To do this, they must rely on innovative technologies and medical solutions, supported by solid data, that will help them coordinate care and reduce preventable hospital readmissions,” said Timothy I. Still, President and CEO of Accumetrics. "The VerifyNow System and our Quality Improvement Program are important tools to help healthcare providers deliver the most clinically appropriate and cost-effective care for patients on antiplatelet medications.”

A cornerstone of Accumetrics’ Quality Improvement Program is the company’s proprietary Value Assessment Model. Based on published data, the model was featured in an award-winning scientific poster at the recent American Association for Clinical Chemistry (AACC) scientific meeting. It can be completed for any hospital by Accumetrics’ team of representatives, and will project reductions in 30-day readmissions and preoperative length of stay. Additionally, Accumetrics’ Clinical Liaisons are available to work directly with clinicians and healthcare institutions to measure the clinical quality and economic impact of implementing platelet reactivity testing as part of clinical practice.

"We are in an interesting era of medicine where we have to be extremely cost conscious while trying to maintain the highest standards in quality care," said Paul Teirstein, chief of cardiology, Scripps Clinic, La Jolla, Calif. "At Scripps, we feel that incorporating platelet reactivity testing provides us critical information to assess the chosen antiplatelet treatment strategy and make any modifications that we feel gives our patients the best chance to remain event-free."

The VerifyNow System is currently used clinically by physicians in more than 800 facilities in the United States and more than 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

For more information:

Related Content

COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing| July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Overlay Init